解析肺腺癌中的RET基因断点
Breaking down RET breakpoints in lung adenocarcinoma.
作者信息
Watanabe Hideo, Brooks Angela N, Meyerson Matthew
机构信息
*Department of Medical Oncology; †Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston; ‡Cancer Program, Broad Institute of Harvard and M.I.T., Cambridge; and §Department of Pathology, Harvard Medical School and Brigham and Women's Hospital, Boston, MA.
出版信息
J Thorac Oncol. 2014 May;9(5):590-2. doi: 10.1097/JTO.0000000000000168.
Abstract
The work by Mizukami et al., published in this issue, describes precise genomic breakpoints on 18 lung adenocarcinoma samples with oncogenic rearrangements, which occur in ~2% of lung adenocarcinomas. Sequence analysis indicates that breakpoints occur at non-specific sites, using variable mechanisms for DNA repair. This study provides important information for the development of molecular tests for this genomic rearrangement.
摘要
水kami等人发表在本期的研究描述了18例具有致癌重排的肺腺癌样本中的精确基因组断点，这种情况约占肺腺癌的2%。序列分析表明，断点出现在非特异性位点，采用了可变的DNA修复机制。这项研究为针对这种基因组重排的分子检测开发提供了重要信息。
相似文献
1
Breaking down RET breakpoints in lung adenocarcinoma.解析肺腺癌中的RET基因断点
J Thorac Oncol. 2014 May;9(5):590-2. doi: 10.1097/JTO.0000000000000168.
2
Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma.肺腺癌中致癌性 RET 融合的分子机制。
J Thorac Oncol. 2014 May;9(5):622-30. doi: 10.1097/JTO.0000000000000135.
3
A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.全基因组和转录组测序揭示肺腺癌中存在一个转化的 KIF5B 和 RET 基因融合。
Genome Res. 2012 Mar;22(3):436-45. doi: 10.1101/gr.133645.111. Epub 2011 Dec 22.
4
ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.ALK、ROS1 和 RET 融合在 1139 例肺腺癌中的综合研究：常见和融合模式特异性临床病理、组织学和细胞学特征。
Lung Cancer. 2014 May;84(2):121-6. doi: 10.1016/j.lungcan.2014.02.007. Epub 2014 Feb 19.
5
Chipping away at the lung cancer genome.逐步破解肺癌基因组。
Nat Med. 2012 Mar 6;18(3):349-51. doi: 10.1038/nm.2697.
6
Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.一种与RET融合的新伙伴基因KIAA1217的鉴定：肺腺癌中两种异构体的功能特性及抑制剂敏感性
Oncotarget. 2016 Jun 14;7(24):36101-36114. doi: 10.18632/oncotarget.9137.
7
Detection of RET (rearranged during transfection) variants and their downstream signal molecules in RET rearranged lung adenocarcinoma patients.在RET重排的肺腺癌患者中检测RET（转染期间重排）变异及其下游信号分子。
Surg Oncol. 2018 Mar;27(1):106-113. doi: 10.1016/j.suronc.2018.01.006. Epub 2018 Feb 8.
8
Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.RET重排在伴有恶性胸腔积液的转移性肺腺癌患者中的临床及预后意义
Lung Cancer. 2015 May;88(2):208-14. doi: 10.1016/j.lungcan.2015.02.018. Epub 2015 Mar 4.
9
RET fusion gene: translation to personalized lung cancer therapy.RET 融合基因：向个体化肺癌治疗的转化。
Cancer Sci. 2013 Nov;104(11):1396-400. doi: 10.1111/cas.12275. Epub 2013 Oct 1.
10
A Novel Intergenic LSM14A-RET Fusion Variant in a Patient With Lung Adenocarcinoma.
J Thorac Oncol. 2020 Apr;15(4):e52-e53. doi: 10.1016/j.jtho.2019.11.025.
本文引用的文献
1
CD74-NRG1 fusions in lung adenocarcinoma.肺腺癌中的 CD74-NRG1 融合。
Cancer Discov. 2014 Apr;4(4):415-22. doi: 10.1158/2159-8290.CD-13-0633. Epub 2014 Jan 27.
2
Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients.东亚人群肺鳞癌的综合比较基因组分析。
J Clin Oncol. 2014 Jan 10;32(2):121-8. doi: 10.1200/JCO.2013.50.8556. Epub 2013 Dec 9.
3
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.肺癌中致癌和药物敏感的 NTRK1 重排。
Nat Med. 2013 Nov;19(11):1469-1472. doi: 10.1038/nm.3352. Epub 2013 Oct 27.
4
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.通过基于激酶组的 RNA 测序鉴定肺癌中的 FGFR3 融合基因。
J Pathol. 2013 Jul;230(3):270-6. doi: 10.1002/path.4209.
5
Identification of targetable FGFR gene fusions in diverse cancers.鉴定多种癌症中可靶向的 FGFR 基因融合。
Cancer Discov. 2013 Jun;3(6):636-47. doi: 10.1158/2159-8290.CD-13-0050. Epub 2013 Apr 4.
6
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.卡博替尼治疗 RET 融合阳性肺腺癌患者的疗效。
Cancer Discov. 2013 Jun;3(6):630-5. doi: 10.1158/2159-8290.CD-13-0035. Epub 2013 Mar 26.
7
Incidence and patterns of ALK FISH abnormalities seen in a large unselected series of lung carcinomas.在一大组未经选择的肺癌系列中观察到的ALK FISH异常的发生率和模式。
Mol Cytogenet. 2012 Dec 3;5(1):44. doi: 10.1186/1755-8166-5-44.
8
KIF5B-RET fusions in lung adenocarcinoma.肺腺癌中的 KIF5B-RET 融合。
Nat Med. 2012 Feb 12;18(3):375-7. doi: 10.1038/nm.2644.
9
RET, ROS1 and ALK fusions in lung cancer.肺癌中的 RET、ROS1 和 ALK 融合。
Nat Med. 2012 Feb 12;18(3):378-81. doi: 10.1038/nm.2658.
10
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.鉴定结直肠癌和肺癌活检组织中的新型 ALK 和 RET 基因融合。
Nat Med. 2012 Feb 12;18(3):382-4. doi: 10.1038/nm.2673.
Zotero 插件